Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Intervalo de año de publicación
1.
Antioxidants (Basel) ; 12(7)2023 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-37507963

RESUMEN

Ethanol consumption triggers oxidative stress by generating reactive oxygen species (ROS) through its metabolites. This process leads to steatosis and liver inflammation, which are critical for the development of alcoholic liver disease (ALD). Autophagy is a regulated dynamic process that sequesters damaged and excess cytoplasmic organelles for lysosomal degradation and may counteract the harmful effects of ROS-induced oxidative stress. These effects include hepatotoxicity, mitochondrial damage, steatosis, endoplasmic reticulum stress, inflammation, and iron overload. In liver diseases, particularly ALD, macroautophagy has been implicated as a protective mechanism in hepatocytes, although it does not appear to play the same role in stellate cells. Beyond the liver, autophagy may also mitigate the harmful effects of alcohol on other organs, thereby providing an additional layer of protection against ALD. This protective potential is further supported by studies showing that drugs that interact with autophagy, such as rapamycin, can prevent ALD development in animal models. This systematic review presents a comprehensive analysis of the literature, focusing on the role of autophagy in oxidative stress regulation, its involvement in organ-organ crosstalk relevant to ALD, and the potential of autophagy-targeting therapeutic strategies.

2.
J Fungi (Basel) ; 8(6)2022 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-35736059

RESUMEN

(1) Background: Aspergillus produces high morbidity and mortality, especially in at-risk populations. In Spain, the evolution of mortality in recent years due to this fungus is not well established. The aim of this study was to estimate the case fatality rate of aspergillosis in inpatients from 1997 to 2017 in Spain. (2) Methodology: A retrospective descriptive study was conducted with records of inpatients admitted to the National Health System with a diagnosis of aspergillosis. (3) Principal findings: Of 32,960 aspergillosis inpatients, 24.5% of deaths were registered, and 71% of the patients who died were men. The percentage of deaths increased progressively with age. The case fatality rate progressively decreased over the period, from 25.4 and 27.8% in 1997-1998 to values of 20.6 and 20.8% in 2016 and 2017. Influenza and pneumonia occurrence/association significantly increased case fatality rates in all cases. (4) Conclusions: Our study shows that lethality significantly decreased in the last two decades despite the increase in cases. This highlights the fact that patients with solid and/or hematological cancer do not have a much higher mortality rate than the group of patients with pneumonia or influenza alone, these two factors being the ones that cause the highest CFRs. We also need studies that analyze the causes of mortality to decrease it and studies that evaluate the impact of COVID-19.

3.
Galicia clin ; 82(1): 38-40, Enero-Febrero-Marzo 2021. ilus
Artículo en Español | IBECS | ID: ibc-221104

RESUMEN

La toma de antagonistas de los receptores de la angiotensina II (ARA II) puede desarrollar una enteropatía similar a la enfermedad celíaca, compartiendo incluso el mismo patrón histopatológico. El desconocimiento de esta entidad puede llevar a errores diagnósticos y terapéuticos. Se presenta el caso de un varón de 69 años, hipertenso en tratamiento con olmesartán, que es valorado por presentar diarrea de dos semanas de evolución, junto con pérdida ponderal de 5 kilogramos. Se realizó una biopsia de duodeno, donde se objetivó un patrón Marsh 3c. Tras la retirada del fármaco se confirma la mejoría clínica. Una segunda biopsia evidenció una regresión histológica a patrón Marsh 3. (AU)


Asunto(s)
Humanos , Masculino , Anciano , Enteropatías Perdedoras de Proteínas , Enteropatías Perdedoras de Proteínas/diagnóstico , Enteropatías Perdedoras de Proteínas/terapia , Olmesartán Medoxomilo/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA